Eva Ciruelos

19.2k total citations · 7 hit papers
208 papers, 7.1k citations indexed

About

Eva Ciruelos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eva Ciruelos has authored 208 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Oncology, 118 papers in Pulmonary and Respiratory Medicine and 79 papers in Cancer Research. Recurrent topics in Eva Ciruelos's work include HER2/EGFR in Cancer Research (104 papers), Advanced Breast Cancer Therapies (100 papers) and Cancer Treatment and Pharmacology (91 papers). Eva Ciruelos is often cited by papers focused on HER2/EGFR in Cancer Research (104 papers), Advanced Breast Cancer Therapies (100 papers) and Cancer Treatment and Pharmacology (91 papers). Eva Ciruelos collaborates with scholars based in Spain, United States and Italy. Eva Ciruelos's co-authors include Javier Cortés, Mario Campone, José Baselga, Andreas Schneeweiß, Sung‐Bae Kim, Jungsil Ro, Emma Clark, Sandra M. Swain, Mark Benyunes and Jean-Marc Ferrero and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Eva Ciruelos

201 papers receiving 7.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

2015 1.4k citations Sandra M. Swain, José Baselga et al. profile →
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2010 891 citations Luca Gianni, Semiglazov Vf et al. profile →
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

2013 700 citations Sandra M. Swain, Sung‐Bae Kim et al. The Lancet Oncology profile →
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

2020 371 citations Eva Ciruelos, Mario Campone et al. Annals of Oncology profile →
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

2023 210 citations Hope S. Rugo, Aditya Bardia et al. profile →
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

2022 204 citations Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology profile →
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2022 176 citations Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Eva Ciruelos

Since Specialization

Citations

This map shows the geographic impact of Eva Ciruelos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Ciruelos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Ciruelos more than expected).

Fields of papers citing papers by Eva Ciruelos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Ciruelos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Ciruelos. The network helps show where Eva Ciruelos may publish in the future.

Co-authorship network of co-authors of Eva Ciruelos

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Ciruelos. A scholar is included among the top collaborators of Eva Ciruelos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Ciruelos. Eva Ciruelos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial	Clinical Cancer Research	Mafalda Oliveira, Eva Ciruelos et al.	0
2	TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy	Therapeutic Advances in Medical Oncology	Aditya Bardia, Lajos Pusztai et al.	16
3	Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)	ESMO Open	Guillermo Villacampa, Tomás Pascual et al.	7
4	HER2DX genomic test in early-stage HER2-positive breast cancer	ESMO Open	Sara M. Tolaney, Nadine Tung et al.	8
5	387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer	Annals of Oncology	Tomás Pascual, Juan Miguel Cejalvo et al.	1
6	LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study	Annals of Oncology	Luca Gianni, Chiun‐Sheng Huang et al.	10
7	SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)	Clinical & Translational Oncology	Francisco Ayala, Silvia Antolín et al.	14
8	Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study breakdown →	Annals of Oncology	Luca Gianni, Chiun‐Sheng Huang et al.	204
9	Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer breakdown →	Journal of Clinical Oncology	Hope S. Rugo, Aditya Bardia et al.	176
10	Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis	OncoImmunology	Alberto Carretero-González, Marta Hergueta‐Redondo et al.	19
11	Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial	European Journal of Cancer	Guillermo Villacampa, Claudette Falato et al.	4
12	Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer	Clinical Cancer Research	Zhen Shi, Julia Wulfkuhle et al.	31
13	Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer	Future Oncology	Miguel Martín, José Á. García-Sáenz et al.	12
14	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer	Clinical Cancer Research	Aleix Prat, Yi‐Hsuan Tsai et al.	5
15	Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study	Breast Cancer Research and Treatment	Francesco Schettini, Navid Sobhani et al.	12
16	Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer	European Journal of Cancer Care	Eva Ciruelos, Dolores Isla et al.	19
17	SEOM clinical guidelines in early stage breast cancer (2018)	Clinical & Translational Oncology	Francisco Ayala, Raquel Andrés et al.	47
18	Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications	Cancer Research	Angelo Gámez‐Pozo, Jorge M. Arevalillo et al.	39
19	Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer	Clinical & Translational Oncology	J. Salvador, Luís Manso et al.	10
20	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study breakdown →	The Lancet Oncology	Sandra M. Swain, Sung‐Bae Kim et al.	700

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact